Table 1 Characteristics of patients receiving LMWH compared to UFH in hemodialysis
Covariates | LMWH | UFH | p value |
|---|---|---|---|
n = 1426 (%) | n = 3370 (%) | ||
Agea (years) ± SD | 67.88 ± 13.7 | 66.57 ± 14.2 | 0.003 |
Sex (Female) | 589 (41.3) | 1316 (39.1) | 0.14 |
Hemodialysis incidence | 1090 (76.4) | 2215 (65.7) | < 0.0001 |
Hospitalization in prior year | 1117 (78.3) | 2678 (79.5) | 0.38 |
Comorbiditiesb | |||
 Cardiovascular disease | 757 (53.1) | 1836 (54.5) | 0.38 |
 Cerebrovascular disease | 121 (8.5) | 315 (9.4) | 0.34 |
 Chronic pulmonary disease | 324 (22.7) | 711 (21.1) | 0.21 |
 Chronic liver disease | 72 (5.1) | 213 (6.3) | 0.09 |
 Congestive heart failure | 473 (33.2) | 1051 (31.2) | 0.18 |
 Diabetes | 796 (55.8) | 1823 (54.1) | 0.27 |
 Hyperlipidemia | 876 (61.4) | 2132 (63.3) | 0.23 |
 Hypertension | 1169 (82.0) | 2614 (77.6) | 0.001 |
 Malignancy | 289 (20.3) | 679 (20.2) | 0.93 |
 Peripheral vascular disease | 407 (28.5) | 992 (29.4) | 0.53 |
 Rheumatoid arthritis | 22 (1.5) | 66 (2.0) | 0.33 |
 Osteoporosis | 92 (6.5) | 205 (6.1) | 0.63 |
 Parathyroidectomy | 0 (0.0) | 10 (0.3) | 0.04 |
 Prior fracture | 34 (2.4) | 100 (3.0) | 0.26 |
Drug usec | |||
 NSAIDs | 743 (52.1) | 1763 (52.3) | 0.89 |
 Steroids | 212 (14.9) | 565 (16.8) | 0.10 |
 Calcium | 872 (61.2) | 2121 (62.9) | 0.24 |
 Vitamin D | 801 (56.2) | 1750 (51.9) | 0.01 |
 Phosphorus chelating agents | 914 (64.1) | 2249 (66.7) | 0.08 |
 Cinacalcet | 14 (1.0) | 18 (0.5) | 0.08 |